Drug Channels

NOVEMBER 19, 2021

Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn describes how oncology pathways were developed to help standardize treatment and ensure quality care. She argues, however, that these pathways often shut manufacturers out of the market. Click here to learn more about MMIT's Pulse Analytics solution , which provides insight into payer- and pathway-driven barriers to access.

Treatment 98

Treatment Marketing Drugs 98

Drug Patent Watch

NOVEMBER 14, 2021

Annual Drug Patent Expirations for AMTURNIDE Amturnide is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. This drug has one…. The post New patent expiration for Novartis drug AMTURNIDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98

Drugs Marketing 98

The Pharma Data

NOVEMBER 19, 2021

Pfizer moment blazoned an agreement with theU.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral seeker, PAXLOVID ™ (PF-07321332; ritonavir), subject to nonsupervisory authorization from theU.S. Food and Drug Administration (FDA). Still, PAXLOVID, which began in Pfizer’s laboratories, If approved or authorized.

Government 52

Government Treatment Clinical Trials Laboratories 52

ProRelix Research

NOVEMBER 17, 2021

Covid 19 Booster Dose – Should we consider it? The idea of booster doses for Covid-19 vaccinations is gaining traction around the world, but India remains a skeptic. Various countries, […]. The post Covid 19 Booster Dose – Should we consider it? appeared first on ProRelix Research.

Vaccine 52

Vaccine Research 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Channels

NOVEMBER 16, 2021

In Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans , I highlighted how those networks have hijacked the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the largest retail chains’ participation in the 21 major 2022 Part D preferred networks that the eight largest plan sponsors will offer.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Patent Watch

NOVEMBER 19, 2021

Annual Drug Patent Expirations for RAYALDEE Rayaldee is a drug marketed by Eirgen and is included in one NDA. It is available from one supplier. There are thirteen patents protecting…. The post New patent for Eirgen drug RAYALDEE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

NIH Director's Blog: Drug Development

NOVEMBER 16, 2021

Credit: Fizkes/Shutterstock Over the course of this pandemic, significant progress has been made in treating COVID-19 and helping to save lives. That progress includes the development of life-preserving monoclonal antibody infusions and repurposing existing drugs , to which NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV ) public-private partnership has made a major contribution.

Clinical Trials 52

Clinical Trials Virus Hospitals FDA 52

Drug Channels

NOVEMBER 18, 2021

In my previous post , I highlighted the largest pharmacy chains that will participate in the 2022 Medicare Part D prescription drug plans (PDP). Today, I examine how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As you will see here, the largest PSAOs are increasingly rejecting preferred networks.

Pharmacy 75

Pharmacy Drugs 75

Drug Patent Watch

NOVEMBER 19, 2021

Annual Drug Patent Expirations for REZUROCK Rezurock is a drug marketed by Kadmon Pharms Llc and is included in one NDA. The generic ingredient in REZUROCK is belumosudil mesylate. Additional…. The post New patent for Kadmon Pharms drug REZUROCK appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

NOVEMBER 18, 2021

– CHALLENGE-MIG is the first and only clinical trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines, Emgality and Nurtec ODT, which work differently – The study’s primary endpoint is the percentage of patients with ?50% reduction from baseline in monthly migraine headache days – The study’s secondary endpoints include quality of life improvements and the percentage of patients with ?

Treatment 52

Treatment Clinical Trials Trials FDA 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Creative Biolabs

NOVEMBER 14, 2021

Vascular dysfunction contributes to the pro-oncogenic tumor microenvironment and impedes the delivery of therapeutic drugs, so normalizing tumor blood vessels may become a potential path. Scientists have developed a new type of therapeutic antibody that may dredge and normalize blood vessels in cancerous tumors, thus providing a more effective drug delivery pathway for targeted cancer treatments, according to a study published on bioRxiv.

Drugs 52

Drugs Therapies Treatment Research 52

Drug Channels

NOVEMBER 15, 2021

Dr. Adam J. Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. Broadcast live on December 17, 2021. 12:00 p.m. to 1:30 p.m. ET This page describes the event and explains how to purchase a registration. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series.

Specialty Pharmacies 94

Specialty Pharmacies Biosimilars Pharmacy Drugs 94

Drug Patent Watch

NOVEMBER 18, 2021

Annual Drug Patent Expirations for TYKERB Tykerb is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent expiration for Novartis drug TYKERB appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

NOVEMBER 18, 2021

— Gilead Exercises Options to Arcus’s Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) — — Arcus to Receive Option Payments Totaling $725 million — Gilead Lores,Inc. (Nasdaq GILD) and Arcus Biosciences,Inc. (NYSE RCUS) moment blazoned that Gilead has exercised its options to three programs in Arcus’s clinical- stage portfolio, including bothanti-TIGIT motes, domvanalimab and

Research 52

Research Small Molecule Clinical Development Packaging 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Plenge Gen

NOVEMBER 15, 2021

[Disclaimers: I am an employee of Bristol Myers Squibb. The views expressed here are my own. Also, I am not a particularly good poker or chess player. It is one reason I am a popular invited guest to poker nights with friends.] I posted on poll on Twitter to ask the question is drug discovery more like poker or chess. There were over 300 responses, with the results split nearly equally (54% poker, 46% chess).

Drugs 52

Drugs 52

Eye on FDA

NOVEMBER 18, 2021

In what has been a glacially paced nomination process, the Biden Administration announced on November 12 that it would, in fact, be nominating Dr. Robert Califf to return to his role as FDA Commissioner. Acting Comissioner Janet Woodcock indicated in a tweet that she would be remaining in the role of Acting Commissioner during the confirmation process.

FDA 57

FDA Pharmaceuticals Pharmaceutical Companies Clinical Research 57

Drug Patent Watch

NOVEMBER 17, 2021

Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. There are three patents protecting this drug. This drug has thirty-six…. The post New patent for Beigene drug BRUKINSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

NOVEMBER 18, 2021

Combined efforts will work to build robust disease models while preserving privacy of large data sets from various research institutions and hospitals Collaboration to focus on four types of cancer. Sanofi blazoned moment an equity investment of$ 180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of$ 90 million for three times plus fresh exploration corner- grounded payments.

Hospitals 52

Hospitals Treatment Pharmaceutical Companies Clinical Trials 52

The Pharma Data

NOVEMBER 18, 2021

KEYTRUDA Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions. KEYTRUDA Is the First Immunotherapy Approved for the Adjuvant Treatment of These Patients With RCC. Merck known as MSD outside the United States and Canada, moment blazoned that theU.S.

FDA Approval 52

FDA Approval FDA Therapies Medical Schools 52

The Pharma Data

NOVEMBER 17, 2021

Approval for the first targeted treatment for eosinophilic granulomatosis with polyangiitis and the first anti-IL-5 biologic treatment for patients with hypereosinophilic syndrome or chronic rhinosinusitis with nasal polyps in Europe Mepolizumab is now the only treatment approved in Europe for use in four eosinophil-driven diseases. GlaxoSmithKline (GSK) plc moment blazoned that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), fo

Disease 52

Disease Treatment Production Drugs 52

The Pharma Data

NOVEMBER 17, 2021

Agreement builds on Pfizer’s comprehensive strategy to work toward equitable access to COVID-19 vaccines and treatments for all people, particularly those living in the poorest parts of the world Agreement will enable qualified sub-licensees to supply countries comprising approximately 53% of the world’s population Interim data from the Phase 2/3 EPIC-HR study demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo in non-hospitalized high-risk adul

Licensing 52

Licensing Licensing Treatment Government 52

The Pharma Data

NOVEMBER 17, 2021

If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2 EUA submission includes clinical data from an interim analysis of the Phase 2/3 EPIC-HR study, which demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death compared to placebo in non-hospitalized high-risk adults with COVID-19 Rolling submissions have commenced in several countries including in

Hospitals 52

Hospitals Licensing Licensing FDA 52

The Pharma Data

NOVEMBER 17, 2021

Pfizer moment blazoned that Frank D’Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply at Pfizer after a nearly 15 time distinguished career with the Company. Pfizer has initiated an external hunt for a new Chief Financial Officer and D’Amelio has agreed to stay on board through this process and serve in a consulting part through the transition.

Vaccine 52

Vaccine Production Government Treatment 52

The Pharma Data

NOVEMBER 17, 2021

Acquisition enhances Pfizer’s Oncology portfolio with addition of coming- generation, investigational immuno- rectifiers for hematological malice. Pfizer moment blazoned the successful completion of its accession of Trillium Rectifiers, a clinical stage immuno-oncology company developing innovative curatives for the treatment of cancer. As Trillium becomes part of Pfizer, it brings an emotional portfolio that includes biologics that are designed to enhance the capability of cases’ ingrain vulner

Biosimilars 52

Biosimilars Government Vaccine Production 52

The Pharma Data

NOVEMBER 17, 2021

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day, hundreds of thousands of new COVID-19 cases and thousands of new deaths are still being reported worldwide, creating a need for drugs that can combat the disease caused by SARS-CoV-2.

Virus 52

Virus Drugs Clinical Trials Medical Schools 52

The Pharma Data

NOVEMBER 17, 2021

VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s leadership in MS oral therapies Phase 3 data have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile European Union authorization follows approvals in United States, Great Britain and Switzerland, providing patients another important option as the

Treatment 52

Treatment Marketing Clinical Trials Biosimilars 52

The Pharma Data

NOVEMBER 17, 2021

BiogenInc. and EisaiCo.,Ltd. (Tokyo, Japan) blazoned moment an update on the ongoing review of the Marketing Authorization Operation for aducanumab 100 mg/ mL concentrate result for infusion for the treatment of Alzheimer’s complaint by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Following an oral explanation held at the November meeting of the CHMP, Biogen entered a negative trend vote on the aducanumab Marketing Authorization Operation.

Clinical Trials 52

Clinical Trials Biosimilars Treatment Trials 52

The Pharma Data

NOVEMBER 17, 2021

Grant to Support New Digital Programs to Reconnect Psoriatic Arthritis Patients with Healthcare Providers. Amgen (NASDAQAMGN) moment blazoned the awarding of a one- time$ entitlement to the Bath Institute of Rheumatic Conditions ( Raspberry) as part of the Understanding Psoriatic Disease Using Perceptivity for Treatment (UPLIFT) Innovation Challenge.

Disease 52

Disease International Treatment Therapies 52

The Pharma Data

NOVEMBER 17, 2021

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months. Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.

Vaccine 52

Vaccine Virus Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 17, 2021

Bayer agronomic moxie and leading digital husbandry platform, combined with Microsoft Azure, form the foundation for new digital results to advance husbandry and conterminous diligence. Moment, Bayer blazoned a strategic cooperation with Microsoft to make a new pall- grounded set of digital tools and data wisdom results for use in husbandry and conterminous diligence, bringing new structure and foundational capabilities to accelerate invention, boost effectiveness and support sustainability acro

Science 52

Science Production 52

Drug Patent Watch

NOVEMBER 17, 2021

Annual Drug Patent Expirations for ABILIFY+MAINTENA+KIT Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. It is available from one supplier.…. The post New patent for Otsuka Pharm drug ABILIFY MAINTENA KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 15, 2021

Annual Drug Patent Expirations for ROZEREM Rozerem is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There is one…. The post New patent expiration for Takeda Pharms drug ROZEREM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 15, 2021

Annual Drug Patent Expirations for PARSABIV Parsabiv is a drug marketed by Kai Pharms Inc and is included in one NDA. It is available from one supplier. There are six…. The post New patent for Kai Pharms drug PARSABIV appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

NOVEMBER 15, 2021

Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. There are three patents protecting this drug. This drug has thirty-six…. The post New patent for Beigene drug BRUKINSA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52